Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03825705CT.gov A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatobiliary Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Catequentinib (this asset) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P1/2 | CCC · 48 |
| Zimberelimab | University of Texas Southwestern Medical Center | P2 | CCC |
| Domvanalimab | University of Texas Southwestern Medical Center | P2 | CCC |
| Olutasidenib | Forma Therapeutics, Inc. | P1/2 | CCC |
| Nivolumab | Forma Therapeutics, Inc. | P1/2 | CCC |
| Cis-Diamminedichloroplatinum Ii | Forma Therapeutics, Inc. | P1/2 | CCC |
| Azacitidine | Forma Therapeutics, Inc. | P1/2 | CCC |
| Benmelstobart | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P1/2 | CCC |
| Trastuzumab Deruxtecan | National Cancer Institute (NCI) | P1 | CC |
+1 more in the Hepatobiliary Neoplasm cohort
Other indications for Catequentinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Refractory Malignant Neoplasm | — | P3 | BB · 70 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BB · 66 |
| Kidney Cancer | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Catequentinib in Hepatobiliary Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/catequentinib-hepatobiliary-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →